SCHEMBL8077322

SCHEMBL8077322

Cc1ccc(C(=O)c2cc(C(C)C)c(O)c(C(C)C)c2)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.72
GABRB1 P18505 1/20 0.72
GAA P10253 3/20 0.62
HTT P42858 2/20 0.62
LMNA P02545 3/20 0.57
ALDH1A1 P00352 1/20 0.57
SRD5A2 P31213 1/20 0.50
SLC6A2 P23975 2/20 0.49
ADRA1A P35348 2/20 0.49
PTGS2 P35354 2/20 0.49
ABCC3 O15438 1/20 0.49
ABCC4 O15439 1/20 0.49
NR1I2 O75469 1/20 0.49
ABCB11 O95342 1/20 0.49
TTR P02766 1/20 0.49
NR3C1 P04150 1/20 0.49
PGR P06401 1/20 0.49
HTR1A P08908 1/20 0.49
ADORA3 P0DMS8 1/20 0.49
RARB P10826 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28078271 0.87 GABRA1 (0.78) GABRA1GABRB1GAAHTTLMNA
SCHEMBL8075582 0.86 GABRA1 (0.72) GABRA1GABRB1GAAHTTLMNA
SCHEMBL2410206 0.84 GABRA1 (0.70) GABRA1GABRB1GAAHTTLMNA
SCHEMBL8075584 0.84 GABRA1 (0.70) GABRA1GABRB1GAAHTTLMNA
SCHEMBL2417465 0.84 GABRA1 (0.70) GABRA1GABRB1GAAHTTLMNA
SCHEMBL2416215 0.84 GABRA1 (0.70) GABRA1GABRB1GAAHTTLMNA
SCHEMBL2413335 0.84 GABRA1 (0.70) GABRA1GABRB1GAAHTTLMNA
SCHEMBL29405385 0.84 GABRA1 (1.00) GABRA1GABRB1GAAHTTLMNA
SCHEMBL8077372 0.81 GABRA1 (0.66) GABRA1GABRB1GAAHTTLMNA
SCHEMBL8067655 0.81 GABRA1 (0.81) GABRA1GABRB1GAAHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114149311-A Method for preparing 4-hydroxybenzophenone compound by taking p-methylenequinone as substrate 上海应用技术大学 2022-03-08 CN disclosed
EP-2520290-A1 Propofol analogs, process for their preparation, and methods of use Abraxis BioScience, LLC (US) 2012-11-07 EP disclosed
US-7825182-B2 Nanocomposite comprising stabilization functionalized thermoplastic polyolefins EXXONMOBIL CHEMICAL PATENTS INC. (US) 2010-11-02 US disclosed
US-7825182-B2 Nanocomposite comprising stabilization functionalized thermoplastic polyolefins EXXONMOBIL CHEMICAL PATENTS INC. (US) 2010-11-02 US disclosed
US-7586008-B2 Propofol analogs, process for their preparation, and methods of use ABRAXIS BIOSCIENCE, INC. (US) 2009-09-08 US disclosed
US-7586008-B2 Propofol analogs, process for their preparation, and methods of use ABRAXIS BIOSCIENCE, INC. (US) 2009-09-08 US disclosed
US-20080275100-A1 PROPOFOL ANALOGS, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE ABRAXIS BIOSCIENCE, INC. (US) 2008-11-06 US disclosed
US-20080275100-A1 PROPOFOL ANALOGS, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE ABRAXIS BIOSCIENCE, INC. (US) 2008-11-06 US disclosed
US-20080214707-A1 Nanocomposite Comprising Stabilization Functionalized Thermoplastic Polyolefins EXXONMOBIL CHEMICAL PATENTS INC. 2008-09-04 US disclosed
US-20080214707-A1 Nanocomposite Comprising Stabilization Functionalized Thermoplastic Polyolefins EXXONMOBIL CHEMICAL PATENTS INC. 2008-09-04 US disclosed
US-7371793-B2 Nanocomposite comprising stabilization functionalized thermoplastic polyolefins EXXONMOBIL CHEMICAL PATENTS INC. (US) 2008-05-13 US disclosed
US-7371793-B2 Nanocomposite comprising stabilization functionalized thermoplastic polyolefins EXXONMOBIL CHEMICAL PATENTS INC. (US) 2008-05-13 US disclosed
US-20070185217-A1 Propofol analogs, process for their preparation, and methods of use ABRAXIS BIOSCIENCE, INC. (US) 2007-08-09 US disclosed
US-20070185217-A1 Propofol analogs, process for their preparation, and methods of use ABRAXIS BIOSCIENCE, INC. (US) 2007-08-09 US disclosed
WO-2005063665-A1 PROPOFOL ANALOGS, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE ABRAXIS BIOSCIENCE, INC (US) 2005-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275100-A1 PROPOFOL ANALOGS, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE CYP3A5, CYP3A4, GABARAP GABRA1 32/4885GABRB1 81/4885GAA 3632/4885
US-20070185217-A1 Propofol analogs, process for their preparation, and methods of use CYP3A5, CYP3A4, GABARAP GABRA1 32/4885GABRB1 81/4885GAA 3632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.